Valuation: ACLS THER

Market Cap 871M 752M 706M 643M 1.21B 83.32B 1.23B 8.27B 3.24B 41.74B 3.27B 3.2B 139B P/E 2026 *
-9.07x
P/E 2027 * -7.32x
Enterprise Value 718M 620M 582M 530M 996M 68.68B 1.01B 6.82B 2.67B 34.41B 2.7B 2.64B 114B EV / Sales 2026 *
114x
EV / Sales 2027 * 140x
Free-Float
97.82%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 17/01/2024
President 67 18/11/2024
Director of Finance/CFO 39 01/01/2023
Director TitleAgeSince
Chairman 56 01/01/2023
Director/Board Member 50 01/09/2014
Director/Board Member 59 01/09/2016
Change 5-day change 1-year change 3-year change Capi.($)
+4.80%+3.44%+70.64%+109.32% 73.25B
+17.12%+11.50%+54.42%+87.30% 61.95B
+3.70%-4.77%+0.41%+484.07% 28.02B
+5.03%+5.44%+56.39%+21.05% 24.15B
-1.60%-1.29%-19.31%-19.10% 23.01B
-6.00%+6.02%+244.39%+430.80% 18.35B
+3.80%+5.62%+40.50%-15.26% 19.46B
+3.54%+2.37%+21.08%+555.76% 15.92B
+2.11%-1.21%+36.57%+149.14% 12.96B
Average +3.61%+0.14%+56.12%+200.34% 30.79B
Weighted average by Cap. +5.95%+2.56%+56.15%+163.99%

Financials

2026 *2027 *
Net sales 6.29M 5.43M 5.09M 4.64M 8.72M 601M 8.84M 59.69M 23.39M 301M 23.6M 23.09M 1B 5.18M 4.47M 4.2M 3.82M 7.19M 495M 7.29M 49.2M 19.28M 248M 19.45M 19.03M 826M
Net income -91.02M -78.58M -73.72M -67.14M -126M -8.7B -128M -864M -339M -4.36B -342M -334M -14.5B -114M -98.61M -92.51M -84.26M -158M -10.92B -161M -1.08B -425M -5.47B -429M -420M -18.2B
Net Debt -153M -132M -124M -113M -212M -14.64B -215M -1.45B -570M -7.33B -575M -562M -24.4B -147M -127M -119M -108M -203M -14.01B -206M -1.39B -545M -7.02B -550M -538M -23.35B
Logo ACLS THER
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-